Precision ovarian cancer drug shows early promise
PharmaTimes Media Ltd | June 05, 2017
An experimental targeted treatment for ovarian cancer has shown promise in early clinical trials shrinking tumours in half of women with the disease. Researchers from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust tested the drug - known in the study as ONX-0801 - in 15 women with ovarian cancer as part of a wider Phase I clinical trial.